Ampio Pharmaceuticals (NYSE:AMPE) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE) in a research report sent to investors on Friday. The firm issued a sell rating on the stock.

Ampio Pharmaceuticals Trading Down 97.0 %

Shares of AMPE stock opened at $0.00 on Friday. Ampio Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $2.47. The firm has a market capitalization of $2,951.00, a PE ratio of 0.00 and a beta of 3.71. The firm has a fifty day simple moving average of $0.02 and a two-hundred day simple moving average of $0.02.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.